PR Newswire·May 4, 2026, 8:30 AM ET

Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment

Approximately one in five working adults with tardive dyskinesia (TD) reported quitting their job due to untreated involuntary movements.
Respondents with TD missed an average of eight hours of work or school per week prior to starting treatment.
The survey was conducted online by Ipsos on behalf of Neurocrine Biosciences between January 15 and February 17, 2026, involving 100 individuals including 70 patients and 30 caregivers.
Findings were released during Tardive Dyskinesia Awareness Week (May 3-9) to highlight the impact of TD on employment, education, and caregiving.
Of the 59 adults with TD who met employment criteria, 12 quit their jobs and 19 stepped down from work responsibilities due to TD symptoms.
The American Psychiatric Association recommends first-line treatment with FDA-approved VMAT2 inhibitors for moderate to severe TD, yet only an estimated one in ten individuals receive this treatment.
TD is estimated to affect at least 800,000 U.S. adults, with approximately 60% remaining undiagnosed.
TD is a chronic movement disorder associated with antipsychotics and gastrointestinal medications, characterized by uncontrolled, repetitive movements that can be persistent or irreversible.